CJC-1295 No DAC vs DAC: What the Research Difference Actually Is

The Drug Affinity Complex is a small chemical moiety covalently attached to the CJC-1295 peptide that binds reversibly to plasma albumin. In research models this binding extends serum half-life from minutes (as with the No DAC variant) into days — the published literature commonly cites half-life values around 5–8 days for the DAC variant versus approximately 30 minutes for the No DAC variant.

From a research-design perspective the DAC variant produces continuous GHRH-receptor engagement; the No DAC variant produces pulsatile, physiological-style stimulation more closely matching endogenous GHRH-release patterns.

The 2006 publications that introduced CJC-1295 (including the JCEM 2006 paper, PMID 16384879) initially highlighted the DAC variant's extended half-life as a research feature. Subsequent literature, including the 2012 Endocrine Reviews paper on GHRH analogs (PMID 22148949), shifted research interest toward pulsatile-stimulation models that better mimic the physiological GH-release axis.

This is why most modern research protocols favor CJC-1295 No DAC — the short half-life allows researchers to study pulsatile-style growth-hormone release rather than continuous receptor activation.

Most CJC-1295 No DAC research protocols pair the compound with Ipamorelin because the two target complementary growth-hormone-release pathways — GHRH-receptor agonism alongside GHS-R (ghrelin-receptor) agonism. We cover the rationale in detail in our CJC-1295 vs Ipamorelin comparison guide.

BioInfinity Lab supplies a pre-blended CJC-1295 + Ipamorelin research vial for protocol convenience, alongside single-compound vials at /buy/cjc-1295-no-dac and /buy/ipamorelin.

Lyophilized CJC-1295 No DAC stores at −20 °C protected from light. Reconstituted with bacteriostatic water at 1–5 mg/mL it refrigerates at 2–8 °C and is typically used within 30 days per laboratory SOP. BioInfinity Lab ships same-day from New York on orders placed before 2 PM ET.